Saranac Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Saranac Partners's BMY Position: Q2 2026 in Review
Saranac Partners increased its Bristol-Myers Squibb (BMY) stake by 1.8% in Q2 2026, buying an estimated $7.46K and bringing the position to 7,311 shares worth $421K. The position accounts for 0.12% of the portfolio, ranked #83.
Saranac Partners first reported a position in BMY in Q1 2023 and has held it in 14 quarters since. The position peaked at $438K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Saranac Partners held 7,311 shares of Bristol-Myers Squibb worth $421K as of Q2 2026.
- Saranac Partners bought 130 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.46K.
- Bristol-Myers Squibb made up 0.12% of Saranac Partners's portfolio in Q2 2026, its #83 holding.
- Saranac Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 14 quarters since.
- Saranac Partners's Bristol-Myers Squibb position peaked at $438K in Q1 2026.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.